Abstract
Background: Transepidermal water loss (TEWL) has historically been used as an objective measure of skin water barrier function and integrity. Variation in TEWL has been associated with variables such as age and anatomic location, yet regulatory agencies provide minimal guidance on controlling for variation in settings such as in vitro permeation testing (IVPT). Suggestions by the FDA broadly advise skin samples with <15 g m-2h-1 TEWL for IVPT studies. However, many variables have been described in the literature that influence TEWL.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call